Curaleaf (OTCMKTS:CURLF - Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.09, Zacks reports. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%. The company had revenue of $331.05 million during the quarter, compared to analyst estimates of $331.87 million.
Curaleaf Stock Down 6.3 %
CURLF traded down $0.07 during trading on Thursday, hitting $1.04. The company had a trading volume of 638,504 shares, compared to its average volume of 741,974. The company has a market capitalization of $687.05 million, a PE ratio of -3.59 and a beta of 0.57. Curaleaf has a one year low of $0.88 and a one year high of $6.40. The firm's 50-day moving average price is $1.43 and its 200 day moving average price is $2.17. The company has a quick ratio of 0.51, a current ratio of 1.11 and a debt-to-equity ratio of 0.85.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. Cormark lowered shares of Curaleaf from a "moderate buy" rating to a "hold" rating in a report on Thursday, November 7th. Roth Capital raised shares of Curaleaf to a "strong-buy" rating in a report on Sunday, November 10th.
View Our Latest Stock Report on Curaleaf
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
